Standout Papers

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Stud... 2010 2026 2015 2020 1.0k
  1. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia (2016)
    Gabriel Étienne, Joëlle Guilhot et al. Journal of Clinical Oncology
  2. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial (2010)
    François‐Xavier Mahon, Delphine Réa et al. The Lancet Oncology

Immediate Impact

15 from Science/Nature 76 standout
Sub-graph 1 of 20

Citing Papers

Principles and therapeutic applications of adaptive immunity
2024 Standout
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
2023 Standout
35 intermediate papers

Works of Franck E. Nicolini being referenced

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
2011
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
2010 Standout
and 19 more

Author Peers

Author Last Decade Papers Cites
Franck E. Nicolini 2610 2053 1195 56 2.9k
Philipp D. le Coutre 2178 1850 1190 72 2.4k
Beatriz Moiraghi 1762 1504 1000 41 2.0k
M. Brigid Bradley‐Garelik 2186 1832 1207 27 2.4k
Concepción Boqué 1946 1598 1006 23 2.2k
Philippe Rousselot 1977 1621 984 31 2.2k
Susanne Saußele 3066 2641 1373 121 3.7k
Stephen G. O’Brien 3709 3058 2017 43 4.4k
Laurence Legros 3531 2662 1492 126 4.0k
Chao Zhu 1788 1496 1009 48 2.2k
Fausto Castagnetti 2285 1906 1209 105 2.7k

All Works

Loading papers...

Rankless by CCL
2026